NovoCure
NVCR
161 hedge funds and large institutions have $1.66B invested in NovoCure in 2018 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 64 increasing their positions, 33 reducing their positions, and 15 closing their positions.
341% more call options, than puts
Call options by funds: $23.2M | Put options by funds: $5.26M
213% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 15
94% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 33
73% more capital invested
Capital invested by funds: $959M → $1.66B (+$696M)
25% more funds holding
Funds holding: 129 → 161 (+32)
9.36% more ownership
Funds ownership: 48.97% → 58.33% (+9.4%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$52.3M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
+$41.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.5M |
| 4 |
BlackRock
New York
|
+$23.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$20.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$14.4M |
| 3 |
SG
StepStone Group
La Jolla,
California
|
-$13.9M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$7.38M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$7.23M |
NVCR Hedge Fund Activity: Q2 2018 in Review
161 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q2 2018, worth a combined $1.66B — up 73% from $959M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new NVCR positions and 15 closed out — a net gain of 32 holders — while 64 added to existing stakes and 33 trimmed.
The largest buyer was Capital World Investors, opening a new position worth an estimated $52.3M. The largest seller was Frontier Capital Management, cutting an estimated $20.9M.
- 161 institutional investors held NovoCure (NVCR) as of Q2 2018, up from 129 in Q1 2018.
- Funds reported $1.66B of NovoCure stock for Q2 2018, up 73% quarter-over-quarter.
- 47 funds opened new NovoCure positions in Q2 2018 and 15 closed out, a net change of +32 holders.
- The largest NovoCure buyer in Q2 2018 was Capital World Investors, an estimated $52.3M added.
- The largest NovoCure seller in Q2 2018 was Frontier Capital Management, an estimated $20.9M sold.
Based on aggregated 13F filings for Q2 2018.